JP2024514339A5 - - Google Patents

Info

Publication number
JP2024514339A5
JP2024514339A5 JP2023564025A JP2023564025A JP2024514339A5 JP 2024514339 A5 JP2024514339 A5 JP 2024514339A5 JP 2023564025 A JP2023564025 A JP 2023564025A JP 2023564025 A JP2023564025 A JP 2023564025A JP 2024514339 A5 JP2024514339 A5 JP 2024514339A5
Authority
JP
Japan
Prior art keywords
substituted
group
membered
heteroatoms selected
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023564025A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024514339A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/025083 external-priority patent/WO2022221704A1/en
Publication of JP2024514339A publication Critical patent/JP2024514339A/ja
Publication of JP2024514339A5 publication Critical patent/JP2024514339A5/ja
Pending legal-status Critical Current

Links

JP2023564025A 2021-04-16 2022-04-15 がんを治療する化合物、組成物、及び方法 Pending JP2024514339A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163175974P 2021-04-16 2021-04-16
US63/175,974 2021-04-16
US202163281493P 2021-11-19 2021-11-19
US63/281,493 2021-11-19
PCT/US2022/025083 WO2022221704A1 (en) 2021-04-16 2022-04-15 Compounds, compositions and methods of treating cancer

Publications (2)

Publication Number Publication Date
JP2024514339A JP2024514339A (ja) 2024-04-01
JP2024514339A5 true JP2024514339A5 (cg-RX-API-DMAC7.html) 2026-06-24

Family

ID=81580947

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023564025A Pending JP2024514339A (ja) 2021-04-16 2022-04-15 がんを治療する化合物、組成物、及び方法

Country Status (14)

Country Link
US (1) US20240228482A1 (cg-RX-API-DMAC7.html)
EP (1) EP4323358A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024514339A (cg-RX-API-DMAC7.html)
KR (1) KR20240037184A (cg-RX-API-DMAC7.html)
AU (1) AU2022256514A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023021068A2 (cg-RX-API-DMAC7.html)
CA (1) CA3215395A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023003068A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023015484A2 (cg-RX-API-DMAC7.html)
IL (1) IL307732A (cg-RX-API-DMAC7.html)
MX (1) MX2023012245A (cg-RX-API-DMAC7.html)
PE (1) PE20240767A1 (cg-RX-API-DMAC7.html)
TW (1) TW202309023A (cg-RX-API-DMAC7.html)
WO (1) WO2022221704A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4359381A4 (en) * 2021-06-21 2025-04-30 Nimbus Clio, Inc. Cbl-b modulators and uses thereof
US20250042896A1 (en) * 2021-10-29 2025-02-06 Hainan Simcere Zaiming Pharmaceutical Co., Ltd. Polycyclic compound as cbl-b inhibitor
US12187709B2 (en) 2021-11-05 2025-01-07 Genentech, Inc. Lactams as CBL-B inhibitors selective over C-CBL
WO2023205180A1 (en) 2022-04-19 2023-10-26 Nurix Therapeutics, Inc. Biomarkers for cbl, and compositions and methods for their use
WO2023250097A1 (en) 2022-06-22 2023-12-28 Nurix Therapeutics, Inc. Combination therapies with cbl-b inhibitor compounds and antiemetic agents
EP4554586A1 (en) * 2022-07-12 2025-05-21 Hotspot Therapeutics, Inc. Cbl-b inhibitors and anti-pd1/anti-pd-l1 for use in the treatment of cancer
JP2025523682A (ja) * 2022-07-12 2025-07-23 ホットスポット セラピューティクス インコーポレイテッド 複素環式化合物の調製方法
KR20250085707A (ko) * 2022-07-12 2025-06-12 핫스팟 세라퓨틱스, 인크. Cbl-b 조절제로서의 트리아진 유도체의 고체 형태
JP2025523058A (ja) * 2022-07-12 2025-07-17 ホットスポット セラピューティクス インコーポレイテッド Clb-b阻害剤と追加の治療剤を併用した細胞増殖関連病態の処置
WO2024015863A1 (en) * 2022-07-12 2024-01-18 Hotspot Therapeutics, Inc. Cbl-b inhibitor, compositions comprising a cbl-b inhibitor in a method of treating a disease associated with cell proliferation
CN119630662A (zh) * 2022-07-18 2025-03-14 英矽智能科技知识产权有限公司 Cbl-b抑制剂及其应用方法
WO2024077244A1 (en) * 2022-10-07 2024-04-11 Hotspot Therapeutics, Inc. Compounds, compositions and methods of treating disorders
WO2024077236A1 (en) * 2022-10-07 2024-04-11 Hotspot Therapeutics, Inc. Compounds, compositions and methods of treating disorders
WO2024086730A1 (en) * 2022-10-19 2024-04-25 Hotspot Therapeutics, Inc. Heterocyclic cbl-b inhibitors for the treatment of cancer
US20260193251A1 (en) 2022-11-16 2026-07-09 Pfizer Inc. Substituted Bicyclic Pyridone Derivatives
WO2024131939A1 (en) * 2022-12-23 2024-06-27 Insilico Medicine Ip Limited Cbl-b inhibitors and methods of uses thereof
EP4653436A1 (en) * 2023-01-19 2025-11-26 Guangzhou Yufan Nantu Biotechnologies Co., Ltd Heterocyclic compounds, preparation method therefor and use thereof
WO2024153246A1 (zh) * 2023-01-20 2024-07-25 海南先声再明医药股份有限公司 取代的三环化合物及其应用
WO2024227436A1 (en) * 2023-05-04 2024-11-07 InventisBio Co., Ltd. Compounds, preparation methods and uses thereof
WO2025067342A1 (zh) * 2023-09-27 2025-04-03 北京望实智慧科技有限公司 用作Cbl-b抑制剂的化合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3740837A1 (de) * 1987-11-27 1989-06-08 Schering Ag Substituierte bicyclische triazole, verfahren zu ihrer herstellung und ihre verwendung als herbizide mittel
BRPI0814441A2 (pt) * 2007-07-19 2015-07-14 Schering Corp Compostos de amida heterocíclica como inibidores de proteína cinase
KR20100072266A (ko) * 2007-10-24 2010-06-30 머크 샤프 앤드 돔 코포레이션 헤테로사이클 페닐 아미드 t-형 칼슘 채널 길항제
US10968216B2 (en) * 2016-10-27 2021-04-06 Bayer Aktiengesellschaft 4,5-annulated 1,2,4-triazolones
EP3573971A1 (en) * 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
EP3733667B1 (en) * 2017-12-26 2024-06-12 Sumitomo Chemical Company, Limited Heterocyclic compounds and noxious arthropod control agent containing same
KR102922115B1 (ko) * 2019-04-09 2026-02-04 누릭스 테라퓨틱스 인코포레이티드 Cbl-b 억제용의 3-치환된 피페리딘 화합물, 및 암 백신 및/또는 종양용해 바이러스와 조합된 cbl-b 억제제의 용도
CA3294689A1 (en) * 2019-06-26 2026-03-02 Nurix Therapeutics, Inc. Substituted benzyl-triazole compounds for cbl-b inhibition, and further uses thereof
JP2020169215A (ja) * 2020-07-15 2020-10-15 住友化学株式会社 複素環化合物を用いる有害節足動物防除方法
IL301690A (en) * 2020-10-16 2023-05-01 Dana Farber Cancer Inst Inc Piperidinyl small molecule degraders of helios and methods of use
KR20250085707A (ko) * 2022-07-12 2025-06-12 핫스팟 세라퓨틱스, 인크. Cbl-b 조절제로서의 트리아진 유도체의 고체 형태
WO2024015863A1 (en) * 2022-07-12 2024-01-18 Hotspot Therapeutics, Inc. Cbl-b inhibitor, compositions comprising a cbl-b inhibitor in a method of treating a disease associated with cell proliferation
JP2025523682A (ja) * 2022-07-12 2025-07-23 ホットスポット セラピューティクス インコーポレイテッド 複素環式化合物の調製方法
EP4554586A1 (en) * 2022-07-12 2025-05-21 Hotspot Therapeutics, Inc. Cbl-b inhibitors and anti-pd1/anti-pd-l1 for use in the treatment of cancer
JP2025523058A (ja) * 2022-07-12 2025-07-17 ホットスポット セラピューティクス インコーポレイテッド Clb-b阻害剤と追加の治療剤を併用した細胞増殖関連病態の処置

Similar Documents

Publication Publication Date Title
CN102105152B (zh) 包含cdks抑制剂和抗肿瘤剂的治疗组合
AU2015207757B2 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of SHP2
JP7592689B2 (ja) Stingアゴニストとしての大環状化合物並びにその方法及び使用
JP2019517549A5 (cg-RX-API-DMAC7.html)
JP7668777B2 (ja) 癌治療
CN112423750A (zh) 用于治疗hiv的衣壳抑制剂
JP2017515802A5 (cg-RX-API-DMAC7.html)
JP2001527066A5 (cg-RX-API-DMAC7.html)
JP2020532556A (ja) 癌を処置するための併用療法
JP2020514311A5 (cg-RX-API-DMAC7.html)
JP2003522163A5 (cg-RX-API-DMAC7.html)
JP2000302693A (ja) 突然死予防のためのコルチコトロピン放出因子アンタゴニスト
JP2021524835A5 (cg-RX-API-DMAC7.html)
CN114867622A (zh) 涉及二芳基巨环化合物的组合疗法
JPWO2021060453A5 (cg-RX-API-DMAC7.html)
JP2019525948A5 (cg-RX-API-DMAC7.html)
JP2012513390A5 (cg-RX-API-DMAC7.html)
JP2013511487A (ja) Cdc7阻害剤と抗新生物薬とを含む治療用の組み合わせ
WO2021018310A1 (zh) 用于治疗非小细胞肺癌的氨基吡啶衍生物
CN112043702A (zh) 用于联合治疗结直肠癌的喹啉类化合物
CN110840893A (zh) 含克莱拉尼的药物组合物及其用途
JP2022535609A5 (cg-RX-API-DMAC7.html)
JP2016514727A5 (cg-RX-API-DMAC7.html)
JP2015516980A5 (cg-RX-API-DMAC7.html)
CN112043832A (zh) 用于联合治疗胃癌的喹啉类化合物